Comment le bénéfice par action récent de AURA se compare-t-il aux attentes ?
Comment les revenus de Aura Biosciences Inc AURA se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Aura Biosciences Inc ?
Quel est le score de qualité des bénéfices pour Aura Biosciences Inc ?
Quand Aura Biosciences Inc publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Aura Biosciences Inc ?
Aura Biosciences Inc a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$5.02
Prix d'ouverture
$4.86
Plage de la journée
$4.73 - $5.06
Plage de 52 semaines
$4.34 - $8.27
Volume
216.0K
Volume moyen
209.2K
BPA (TTM)
-1.93
Rendement en dividend
--
Capitalisation boursière
$321.3M
Qu’est-ce que AURA ?
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The company is headquartered in Boston, Massachusetts and currently employs 106 full-time employees. The company went IPO on 2021-10-29. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. The company is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.